Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Advanced Hodgkin lymphoma—balancing toxicity and cure

(2011) Sean H. Lim et al.   Nature Reviews Clinical Oncology

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

(2011) Simonetta Viviani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Beyond chemotherapy: new agents for targeted treatment of lymphoma

(2010) Anas Younes   Nature Reviews Clinical Oncology

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

(2010) Andreas Engert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma?

(2010) Yasuhiro Oki et al.   Current Hematologic Malignancy Reports

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

(2009) Andreas Engert et al.   JOURNAL OF CLINICAL ONCOLOGY

B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models

(2008) Samuel Kim et al.   JOURNAL OF IMMUNOTHERAPY

Treatment of Hodgkin lymphoma: the past, present and future

(2008) Andrew M Evens et al.   Nature clinical practice. Oncology